Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
Choong kun Lee, Hong Jae Chon, Jaekyung Cheon, Myung Ah Lee, Hyeon Su Im, Joung Soon Jang, Min Hwan Kim, Sejung Park, Beodeul Kang, Moonki Hong, Jin Won Kim, Hyung Soon Park, Myoung Joo Kang, Young Nyun Park, Hye Jin Choi
Research output: Contribution to journal › Article › peer-review
80Scopus
citations
Fingerprint
Dive into the research topics of 'Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)'. Together they form a unique fingerprint.